Capital deployed:

£384,000 SEIS qualifying

Use of funds:

  • Expansion of team
  • Protype optimisation
  • Build out current datasets

Capital deployed:

£384,000 SEIS qualifying

Use of funds:
  • Expansion of team
  • Protype optimisation
  • Build out current datasets
InvenireX is an early-stage technology company combining computational science and synthetic biology to disrupt the PCR market. 
 
The business is based in Newcastle and the management team, led by founder and CEO Dan Todd, has a strong background across DNA nanotechnology, synthetic biology, and computer science. 
 
DSW Ventures made a £385,000 SEIS investment in February 2024, allowing management to complete prototype optimisation and initiate proof-of-concept studies with industry partners. 
Scroll to Top